Literature DB >> 16563315

Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation.

Barry Fortner1, Scott Baldwin, Lee Schwartzberg, Arthur C Houts.   

Abstract

The Cancer Care Monitor (CCM) is a tablet computer-based multidimensional measure of symptom burden and quality of life. This study examined individual item validity for 42 items measuring general physical symptoms and treatment side effects. Patients (40 females and 20 males) completed the CCM and a blinded nurse interview. In general, patient self-reported symptoms on the CCM corresponded well to nurse-verified evaluations. There was excellent agreement between the patient-reported CCM items and nurses' ratings on whether the symptom was present or absent and on the severity of a given symptom. Additionally, the results suggested that the majority of items had high sensitivity, specificity, positive predictive value, negative predictive value, and Youden's Index score. Taken together, the results suggest that the CCM can provide an efficient method for collecting information about symptom presence and symptom burden at the point of care.

Entities:  

Mesh:

Year:  2006        PMID: 16563315     DOI: 10.1016/j.jpainsymman.2005.07.009

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  18 in total

1.  Use of an electronic patient-reported outcome measurement system to improve distress management in oncology.

Authors:  Sophia K Smith; Krista Rowe; Amy P Abernethy
Journal:  Palliat Support Care       Date:  2013-10-16

2.  Longitudinal patient-reported performance status assessment in the cancer clinic is feasible and prognostic.

Authors:  Sang-Yeon Suh; Thomas W Leblanc; Rebecca A Shelby; Gregory P Samsa; Amy P Abernethy
Journal:  J Oncol Pract       Date:  2011-11       Impact factor: 3.840

3.  Patient Experience After Receiving a Diagnosis of Gastric Cancer in the USA.

Authors:  Lisa M Hess; Zhanglin Lin Cui; Yixun Wu; Xiaohong Li; Astra M Liepa; Sarah M Abraham; William Schelman
Journal:  J Gastrointest Cancer       Date:  2018-03

4.  Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients.

Authors:  Amy P Abernethy; James E Herndon; April Coan; Tina Staley; Jane L Wheeler; Krista Rowe; Sophia K Smith; H Shaw; H Kim Lyerly
Journal:  Support Care Cancer       Date:  2010-02-09       Impact factor: 3.603

5.  The differences in the assessments of side effects at an oncology outpatient clinic.

Authors:  A Bayraktar-Ekincioglu; E Kucuk
Journal:  Int J Clin Pharm       Date:  2018-01-20

6.  Real-world outcomes in patients with unresected stage III non-small cell lung cancer.

Authors:  Kellie J Ryan; Karen E Skinner; Ancilla W Fernandes; Rajeshwari S Punekar; Melissa Pavilack; Mark S Walker; Noam A VanderWalde
Journal:  Med Oncol       Date:  2019-01-31       Impact factor: 3.064

7.  The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer.

Authors:  Edward J Stepanski; Mark S Walker; Lee S Schwartzberg; L Johnetta Blakely; Jason C Ong; Arthur C Houts
Journal:  J Clin Sleep Med       Date:  2009-04-15       Impact factor: 4.062

8.  Evaluation of a tablet PC technology to screen and educate oncology patients.

Authors:  Tami L Mark; Barry Fortner; Gina Johnson
Journal:  Support Care Cancer       Date:  2007-08-18       Impact factor: 3.603

9.  Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.

Authors:  Mark S Walker; Edward J Stepanski; Carolina Reyes; Sacha Satram-Hoang; Arthur C Houts; Lee S Schwartzberg
Journal:  Ther Adv Hematol       Date:  2011-06

10.  The impact of remission status on patients' experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data.

Authors:  Neha Kayastha; Steven P Wolf; Susan C Locke; Gregory P Samsa; Areej El-Jawahri; Thomas W LeBlanc
Journal:  Support Care Cancer       Date:  2017-11-18       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.